September 28, 2016

Theratechnologies to Move Forward with Development of new Single Vial Formulation for EGRIFTA® (Tesamorelin for Injection)

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it will move forward with the development of the F4 single vial formulation instead of the 2mg/vial presentation. The introduction of a single vial presentation was part of commitments required by the FDA when it approved EGRIFTA®.